Mauricio Garcia, MD
Interventional Pain Medicine · Overland Park, KSNPI 1942284427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,578 of the $7,853 with a category attached, or 83.8%. 29 manufacturers reported payments, led by Abbott at 28.3% of the total. Reporting peaked in 2021 at $3,105 and has fallen 94.6% since, to $166 in 2024.
Across 154 payments — averaging $50.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- GE HealthCare$1K
- Choice Spine, LLC$909
- Spinesmith Holdings, LLC$511
- Nevro Corp.$368
- Spinal Elements, Inc.$351
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,27516%
- Food & beverage$6,57884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 79 | $2,222 |
| GE HealthCare | 3 | $1,394 |
| Choice Spine, LLC | 3 | $909 |
| Spinesmith Holdings, LLC | 2 | $511 |
| Nevro Corp. | 3 | $368 |
| Spinal Elements, Inc. | 2 | $351 |
| Vertiflex, Inc. | 6 | $297 |
| Precision Spine, Inc. | 3 | $288 |
| AbbVie | 19 | $278 |
| Baudax Bio Inc. | 6 | $207 |
| Sanara Medtech Inc. | 1 | $151 |
| Ulrich Medical USA, Inc. | 1 | $125 |
| Amgen | 2 | $124 |
| Curiteva, Inc. | 1 | $101 |
| Collegium Pharmaceutical, Inc. | 6 | $89 |
| Boston Scientific | 1 | $76 |
| Biocomposites Inc | 1 | $69 |
| Stryker | 1 | $51 |
| Medtronic | 2 | $47 |
| Pfizer | 3 | $38 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Forte Bio-pharma LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Merck | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Spine Wave, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Blackhawk$679
- Tiger Shark$679
- Blackbird$679
- Tomcat$679
- VEO$679
- Proclaim IPG$433
- Medical Device$351
- Proclaim Family of SCS IPGs$278
- Vault C$269
- PROCLAIM$266
- Blackhawk Ti$229
- Boomerang$229
- Stratofuse$229
- Raven Lumbar Plate System$229
- Tiger Shark C$229
- CellerateRx$151
- Senza Spinal Cord Stimulation System$140
- Superion ISS$131
- Omnia$131
- ANJESO$125
How this compares
Too few interventional pain medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 25 | $35,376 |
| MovantikNaloxegol Oxalate | 58 | $23,983 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 355 | $13,122 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $12,204 |
| Lidocaine | 104 | $8,675 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 291 | $8,533 |
| NucyntaTapentadol Hcl | 12 | $8,377 |
| Oxycodone Hcl | 569 | $8,092 |
| Gabapentin | 454 | $5,213 |
| Tizanidine Hcl | 313 | $4,406 |
| Xtampza ErOxycodone Myristate | 12 | $3,456 |
| Cyclobenzaprine Hcl | 256 | $3,003 |
| Pregabalin | 123 | $2,508 |
| Ondansetron OdtOndansetron | 35 | $2,234 |
| Baclofen | 141 | $2,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $278 | $35,37625 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er | $89 | $11,83324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Kansason file to place this against a meaningful peer group, so we don't.
Other interventional pain medicine in Overland Park
- Daniel KlosterOverland Park$876K
- Matthew NadlerOverland Park$5K
- Mark PinkertonOverland Park$177
- Manoj JagtianiHays$7K
- Mackenzie AndersonKansas City$4K
- Eugerie HanleyGalena$2K
- Roger MisasiPittsburg$2K
- Michael HearndonGalena$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.